- Codexis, Inc. (NASDAQ:CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022.
- After ten years of leading the transformation and growth of Codexis, the current President and CEO, John Nicols, will step down for personal reasons.
- Mr. Nicols will remain on Codexis’ Board through the annual meeting in June 2023 and will assume a new multi-year role as Strategic Advisor to provide ongoing support to the company.
- Most recently, Dr. Stephen Dilly served as President and CEO of Sierra Oncology through its recent sale to GlaxoSmithKline (NYSE:GSK) for $1.9 billion.
- Previously, he served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. He holds an MBBS and a Ph.D. in Cardiac Physiology from the University of London.
- Recently,
- Last week, Codexis released the preliminary revenue expectations for Q2, which were lower than the prior guidance.
- Price Action: CDXS shares are trading lower by 2.79% at $6.62 during the post-market session on Monday.
US Weekly Jobless Claims Might Increase To This Level, Here Are The Major Macro Issues For Thursday
U.S. stocks closed mostly higher on Wednesday with the Nasdaq 100 gaining around 100 points amid a rise in Amazon.com, Inc. (NASDAQ: AMZN) and Apple Inc. (NASDAQ: AAPL) shares.
